Learn more

LENZ HEINZ-JOSEF

Overview
  • Total Patents
    43
About

LENZ HEINZ-JOSEF has a total of 43 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are MDXHEALTH SA, RESPONSE GENETICS INC and SYNERGENZ BIOSCIENCE LTD.

Patent filings in countries

World map showing LENZ HEINZ-JOSEFs patent filings in countries
# Country Total Patents
#1 United States 25
#2 WIPO (World Intellectual Property Organization) 18

Patent filings per year

Chart showing LENZ HEINZ-JOSEFs patent filings per year from 1900 to 2020

Focus industries

# Industry
#1 Biotechnology
#2 Pharmaceuticals
#3 Measurement

Top inventors

# Name Total Patents
#1 Lenz Heinz-Josef 43
#2 Zhang Wu 7
#3 Stoehlmacher Jan 3
#4 Park David Jong-Han 2
#5 Xiong Yi Ping 1
#6 Petasis Nicos A 1
#7 Pullarkat Sheeja Thankappan 1
#8 Stebbing Justin 1

Latest patents

Publication Filing date Title
US2014005064A1 Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
US2012289592A1 Ercc1 gene expression level is associated with clinical outcomes in esophageal cancer patients
US2012289424A1 Igf1r polymorphism predicts tumor recurrence in breast cancer patients
US2012289410A1 Genetic variant in formyl peptide receptor 2 (fpr2) predicts clinical outcome in cancer patients
US2012077685A1 Intratumoral gene expression levels of tp and vegf are associated with clinical outcomes in rectal cancer patients treated with 5-fluorouracil and pelvic radiation
WO2011146406A1 Germline polymorphisms in vegf predict clinical outcomes in cancer patients treated with sorafenib
WO2011146405A1 Egf +61g/a and ts 5'utr 2r/3r polymorphisms predict clinical outcomes in cancer patients undergoing anti-egfr therapy
WO2010124218A2 Genetic variants in il-6, p53, mmp-9 and cxcr predict clinical outcome in patients with cancer treated with anti-vegf therapy
US2012108445A1 Vegf and vegfr1 gene expression useful for cancer prognosis
WO2010124239A2 Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
US2010286179A1 EGFR polymorphisms predict gender-related treatment
WO2009140556A2 Genotype and expression analysis for use in predicting outcome and therapy selection
US2010099720A1 Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy
WO2008088855A2 Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
WO2007103823A2 Genetic markers for predicting disease and treatment outcome